Computed Tomography-Based Tumor Heterogeneity Analysis Reveals Differences in a Cohort with Advanced Pancreatic Carcinoma under Palliative Chemotherapy.
Computed tomography
Image analysis
Image biomarker
Pancreatic cancer
Tumor heterogeneity
Journal
Visceral medicine
ISSN: 2297-4725
Titre abrégé: Visc Med
Pays: Switzerland
ID NLM: 101681546
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
24
03
2019
accepted:
17
02
2020
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
ppublish
Résumé
Imaging in pancreatic cancer is a challenge, especially regarding therapy response evaluation. Tumor size, attenuation, and perfusion are widely used as parameters for computed tomography (CT) examinations, but are often limited due to blurry tumor borders and missing qualitative parameters. To improve monitoring of therapy response, we tested a new CT-based approach of tumor heterogeneity feature analysis. A total of 13 patients with pancreatic adenocarcinoma undergoing abdominal CT according to standard as baseline imaging with clinical follow-up and imaging (median time span 64 days) under systematic therapy (FOLFIRINOX/gemcitabine) were retrospectively analyzed. Progression was defined as new lesions and local tumor spread. Tumor heterogeneity analysis was performed using mintLesion®. Seven different image features referring to image heterogeneity were analyzed. Statistical analysis was performed with Spearman's rank correlation and Mann-Whitney U test. During follow-up, tumor volume did not significantly change between our groups with overall progression (local and systemic) and progression-free patients ( Results suggest that analysis of tumor heterogeneity might provide valuable information from routine-acquired images regarding therapy response evaluation. This might help adjusting therapy regimes and could be easily integrated in clinical workflows. Furthermore, this procedure might possibly predict therapy response and, hence could lead the way to find a potential marker for progression-free survival.
Identifiants
pubmed: 33718486
doi: 10.1159/000506656
pii: vis-0037-0077
pmc: PMC7923898
doi:
Types de publication
Journal Article
Langues
eng
Pagination
77-83Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Radiology. 2011 Oct;261(1):165-71
pubmed: 21813743
NPJ Precis Oncol. 2019 Oct 4;3:25
pubmed: 31602401
Eur Radiol. 2019 Dec;29(12):6880-6890
pubmed: 31227882
Crit Rev Oncol Hematol. 2019 Jun;138:44-50
pubmed: 31092384
Medicine (Baltimore). 2019 Jan;98(1):e13963
pubmed: 30608433
Pract Radiat Oncol. 2017 Mar - Apr;7(2):120-125
pubmed: 28274396
Cancer Imaging. 2018 Dec 5;18(1):46
pubmed: 30518436
BMC Med Imaging. 2017 Jun 19;17(1):38
pubmed: 28629416
Acta Radiol. 2019 Sep;60(9):1084-1093
pubmed: 30612433
Sci Rep. 2017 May 26;7(1):2452
pubmed: 28550313
Rev Invest Clin. 2017 Mar-Apr;69(2):66-76
pubmed: 28453505
Ther Adv Med Oncol. 2017 Mar;9(3):159-170
pubmed: 28344661
Front Oncol. 2019 Jun 12;9:494
pubmed: 31245294
Semin Ultrasound CT MR. 2019 Dec;40(6):436-468
pubmed: 31806145
Pancreas. 2019 Oct;48(9):1195-1203
pubmed: 31593021
Eur Radiol. 2020 Jan;30(1):195-205
pubmed: 31392481
Insights Imaging. 2012 Dec;3(6):573-89
pubmed: 23093486
Eur J Radiol. 2017 May;90:152-158
pubmed: 28583627
Cancer Treat Res. 2019;178:209-236
pubmed: 31209847
Abdom Imaging. 2015 Oct;40(7):2331-7
pubmed: 25968046
AJR Am J Roentgenol. 2019 Aug;213(2):349-357
pubmed: 31012758
Case Rep Oncol Med. 2017;2017:7834702
pubmed: 28373919
Radiology. 2016 Sep;280(3):940-8
pubmed: 27031994
AJR Am J Roentgenol. 2016 Jul;207(1):96-105
pubmed: 27145377
Surg Oncol. 2017 Mar;26(1):105-115
pubmed: 28317579